Abiopharma

🔍 Maraoui Claude (Director)

Company: Journey Medical Corp (DERM)

Report Date: 2025-08-25

Detailed Transactions and Holdings:

• Acquired 1,250,000 shares of Common Stock, $0.0001 par value at $0.065 per share (Direct)
  Date: 2025-08-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,397,590.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 10,877 shares of Common Stock, $0.0001 par value at $7.47 per share (Direct)
  Date: 2025-08-25 | Code: F | equity_swap_involved: 0 | shares_owned_after: 2,386,713.00 | transaction_form_type: 4
• Sold 1,250,000 shares of Stock Option (Right to Buy) at $0.065 per share (Derivative)
  Date: 2025-08-25 | Code: M | Expires: 2025-10-19 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Due to administrative error, the number of non-derivative securities beneficially owned by the reporting person was incorrectly reported as 2,397,590 instead of 1,147,590 on a Form 4 filed on June 20, 2025. This column reflects the corrected balance, as effected by the transactions reported on this Form 4.
• F2: On October 19, 2015, the reporting person was granted 1,250,000 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that vested in accordance with the following schedule: 412,500 shares on January 7, 2016, 250,000 shares on September 22, 2016, 337,500 shares on January 7, 2017 and 250,000 shares on September 22, 2017. The 1,250,000 stock options are due to expire on October 19, 2025. Accordingly, the reporting person is exercising the stock options within the 60 days prior to the expiration date.